SAN DIEGO, June 10, 2025 (GLOBE NEWSWIRE) -- Gyre Therapeutics (Nasdaq: GYRE), a commercial-stage biopharmaceutical company, has announced the commencement of a Phase 1 clinical trial for F230, targeting pulmonary arterial hypertension (PAH). The first volunteer has been successfully dosed in this trial, which aims to evaluate the safety, tolerability, and pharmacokinetics of F230 in healthy volunteers. This trial signifies Gyre's expansion into the PAH field, a condition with limited treatment options. F230, a novel endothelin A receptor antagonist, is designed to mitigate pulmonary vascular remodeling and reduce pulmonary pressure. Results from this Phase 1 trial have not yet been presented.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。